Expertise in
1
conditions

Costas K. Yannakou

Melbourne, VIC, AU 
Expertise in
1
conditions
Melbourne, VIC, AU 

Overview

Costas Yannakou practices practicing medicine in Melbourne, Australia.

Mr. Yannakou is highly rated in 1 condition, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Angioimmunoblastic T-cell Lymphoma, Peripheral T-Cell Lymphoma, B-Cell Lymphoma, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 32 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Melbourne, VIC, Australia
Other Locations
Parkville, VIC, Australia
Parkville, NSW, Australia
Epworth Healthcare
East Melbourne, VIC, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1a/1b Dose Escalation and Dose Expansion, First-in-human, Open-Labeled Study of ETH-155008 in Subjects With Relapsed or Refractory B-cell NHL, CLL/SLL and AML
A Phase 1a/1b Dose Escalation and Dose Expansion, First-in-human, Open-Labeled Study of ETH-155008 in Subjects With Relapsed or Refractory B-cell NHL, CLL/SLL and AML
Enrollment Status: Terminated
Publish Date: October 11, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High Risk Myelodysplastic Syndrome
A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High Risk Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: August 31, 2023
Intervention Type: Drug
Study Drug: CB-5339
Study Phase: Phase 1
View 1 Less Clinical Trial

32 Total Publications

LTB-TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma.
LTB-TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma.
Journal: British journal of haematology
Published: May 28, 2026

Frequently Asked Questions about Costas K. Yannakou

Is Costas K. Yannakou a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Costas K. Yannakou is classified as an Advanced expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Costas K. Yannakou participate in research or clinical trials?

Yes. Costas K. Yannakou has published 32 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Costas K. Yannakou's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Yannakou's expertise for a condition
ConditionClose
      View All 19 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile